U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28FO8P.2Na
Molecular Weight 516.4055
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE SODIUM PHOSPHATE

SMILES

C[C@]1([H])C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)COP(=O)([O-])[O-])O)O)F.[Na+].[Na+]

InChI

InChIKey=PLCQGRYPOISRTQ-FCJDYXGNSA-L
InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C22H28FO8P
Molecular Weight 470.4259
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/67018038

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

1.45799997E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral (total)
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
n = 21
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Population Size: 21
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Effects of dexamethasone on tumor-induced brain edema and its distribution in the brain of monkeys.
1979 Mar
ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function.
1999 Apr
Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression.
1999 Apr
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
1999 Aug 12
The glucocorticoid receptor is essential for maintaining basal and dexamethasone-induced repression of the murine corticosteroid-binding globulin gene.
1999 Aug 20
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
1999 Feb
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
1999 Jul
[Iatrogenic Cushing syndrome and mutatio tarda caused by dexamethasone containing nose drops].
1999 Jul
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.
1999 Jun
Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.
1999 Mar
Pharmacological validation of a feline model of steroid-induced ocular hypertension.
1999 Mar
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment.
1999 May
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes.
1999 May 15
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
1999 Nov
Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants.
1999 Nov
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna.
1999 Oct
Dexamethasone increases eNOS gene expression and prevents renal vasoconstriction induced by cyclosporin.
1999 Sep
Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus.
1999 Sep
Morphine induced allodynia in a child with brain tumour.
1999 Sep 4
Dexamethasone enhances ras-recision gene expression in cultured murine fetal lungs: role in development.
2000 Aug
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Dexamethasone-suppressible hypertension.
2000 Aug 26
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
2000 Dec 15
Antenatal dexamethasone enhances endothelin receptorB expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000 Feb
Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw.
2000 Jan 14
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription.
2000 Jun
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.
2000 Jun
Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.
2000 Jun
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.
2000 Jun
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
2000 Mar
Ticlopidine-induced aplastic anemia: development of chromosomal abnormalities and response to immunosuppressive therapy.
2000 Mar
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
2000 May-Jun
Corticosteroids and cognitive function in humans: methodological considerations.
2000 May-Jun
Regulation of leptin release by troglitazone in human adipose tissue.
2000 Nov
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.
2000 Nov
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.
2000 Sep
Modification of biophysical properties of lung epithelial Na(+) channels by dexamethasone.
2000 Sep
Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats.
2000 Sep 8
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
2009 Jul 1
Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.
2012 Jun
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
2012 Jun
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
2012 Nov
Patents

Sample Use Guides

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In mild disease, drops may be used up to four to six times daily.
Route of Administration: Other
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:03:56 UTC 2021
Edited
by admin
on Fri Jun 25 21:03:56 UTC 2021
Record UNII
AI9376Y64P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE SODIUM PHOSPHATE
EP   GREEN BOOK   JAN   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [VANDF]
Common Name English
DEXABENE
Brand Name English
MEPHAMESONE
Brand Name English
DEXADRESON
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [WHO-DD]
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [WHO-IP]
Common Name English
MEGACORT
Common Name English
ORADEXON
Brand Name English
TLC-399
Code English
DEXACORT
Brand Name English
DEXAMETHASONE DISODIUM PHOSPHATE
Common Name English
PRODEX
Brand Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-(DIHYDROGEN PHOSPHATE) DISODIUM SALT
Common Name English
SOLUDECADRON
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17-DIHYDROXY-16-METHYL-21-(PHOSPHONOOXY)-, DISODIUM SALT, (11.BETA.,16.ALPHA.)-
Common Name English
TLC399
Code English
AK-DEX
Brand Name English
DALALONE
Brand Name English
DEXAMETHASONE SODIUM PHOSPHATE [JAN]
Common Name English
NSC-756722
Code English
DEXAMETHASONE SODIUM PHOSPHATE [GREEN BOOK]
Common Name English
DEXAMETHASONE PHOSPHATE (AS SODIUM)
Common Name English
TOTOCORTIN
Brand Name English
DEXACEN-4
Brand Name English
DEXAMETHASONE 21-PHOSPHATE DISODIUM SALT [MI]
Common Name English
ORGADRONE
Brand Name English
SOLDESAM
Brand Name English
NEODECADRON COMPONENT DEXAMETHASONE SODIUM PHOSPHATE
Common Name English
DEXAIR
Brand Name English
DEXAMETHASONE SODIUM PHOSPHATE [USP MONOGRAPH]
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE COMPONENT OF NEODECADRON
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [ORANGE BOOK]
Common Name English
DEXAMETHASONE 21-PHOSPHATE DISODIUM SALT
MI  
Common Name English
TURBINAIRE
Common Name English
SOLUPEN N
Brand Name English
DEXAMETHASONI NATRII PHOSPHAS [WHO-IP LATIN]
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [USP-RS]
Common Name English
DECADRON PHOSPHATE
Brand Name English
DEXAMETHASONE SODIUM PHOSPHATE [MART.]
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [USP]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 373212
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
EU-Orphan Drug EU/3/13/1158
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
Code System Code Type Description
PUBCHEM
16961
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
RXCUI
48933
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
219-243-0
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201302
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
NCI_THESAURUS
C1362
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
FDA UNII
AI9376Y64P
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
DRUG BANK
DBSALT000843
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
CAS
2392-39-4
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
MERCK INDEX
M4215
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY Merck Index
EVMPD
SUB01615MIG
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
EVMPD
SUB122698
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
ALTERNATIVE
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE SODIUM PHOSPHATE
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder.Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/L) TS; practically insoluble in dichloromethane R.Category: Adrenal hormone.Storage: Dexamethasone sodium phosphate should be kept in a tightly closed container, protected from light.Additional information: Dexamethasone sodium phosphate is very hygroscopic. Even in the absence of light it is graduallydegraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Dexamethasone sodiumphosphate may exhibit polymorphism.
USP_CATALOG
1177032
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY USP-RS
EPA CompTox
2392-39-4
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
MESH
C004180
Created by admin on Fri Jun 25 21:03:56 UTC 2021 , Edited by admin on Fri Jun 25 21:03:56 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity A by 0.75
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY